Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [11] Chemotherapy in metastatic castration resistant prostate cancer
    Rosino, Antonio
    Ballester, Inmaculada
    Tudela, Julian
    Gonzalez-Billalabeitia, Enrique
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 676 - 684
  • [12] The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer
    Chen, Zhibin
    Chen, Ni
    Shen, Pengfei
    Gong, Jing
    Li, Xiang
    Zhao, Tao
    Liao, Banghua
    Liu, Liangren
    Liu, Zhenhua
    Zhang, Xingming
    Liu, Jiyan
    Peng, Zhufeng
    Chen, Xueqin
    Xu, Miao
    Gui, Haojun
    Zhang, Peng
    Wei, Qiang
    Zhou, Qiao
    Zeng, Hao
    PROSTATE, 2015, 75 (12): : 1247 - 1254
  • [13] The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [14] PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
    Al-Akhras, Ashaar
    Chehade, Chadi Hage
    Narang, Arshit
    Swami, Umang
    LIFE-BASEL, 2024, 14 (02):
  • [15] Real-world treatment landscape in advanced metastatic castration resistant prostate cancer
    Sacchi, Elizabeth
    Singhal, Hari
    Zamalloa, Jose
    Sanchez, Beatriz Lopez
    Zhang, Ke
    Parihar, Harish
    Greshock, Joel
    Max, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [16] Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer
    Al-Mansouri, Loma
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (06) : 288 - 295
  • [17] Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Zobniw, Chrystia M.
    Causebrook, Alanna
    Fong, Mei Ka
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 97 - 105
  • [18] Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
    Stein, Cy A.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : 407 - 409
  • [19] Clinical and genomic resistance to second generation androgen blockade in paired biopsies of metastatic castration-resistant prostate cancer
    Han, G. Celine
    Hwang, Justin
    Mullane, Stephanie A.
    Cibulskis, Carrie
    Zhang, Zhenwei
    McKay, Rana R.
    Carter, Scott L.
    Hahn, William C.
    Taplin, Mary-Ellen
    Van Allen, Eliezer M.
    CANCER RESEARCH, 2017, 77
  • [20] A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer
    Seisen, Thomas
    Roupret, Morgan
    Gomez, Florie
    Malouf, Gabriel G.
    Shariat, Shahrokh F.
    Peyronnet, Benoit
    Spano, Jean-Philippe
    Cancel-Tassin, Geraldine
    Cussenot, Olivier
    CANCER TREATMENT REVIEWS, 2016, 48 : 25 - 33
12345